| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 72572-0020-01 | 72572-0020 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sep 12, 2025 | In Use | |
| 55154-7143-00 | 55154-7143 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Aug 12, 2008 | Sep 30, 2024 | No Longer Used |
| 25021-0207-05 | 25021-0207 | Doxorubicin Hydrochloride | doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Oct 31, 2013 | Sep 30, 2020 | No Longer Used |
| 68001-0643-06 | 68001-0643 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 18, 2025 | In Use | |
| 63304-0095-11 | 63304-0095 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | In Use | |
| 43975-0253-14 | 43975-0253 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jul 13, 2016 | In Use | |
| 65219-0566-20 | 65219-0566 | MITOMYCIN | MITOMYCIN | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jan 15, 2023 | In Use | |
| 31722-0782-30 | 31722-0782 | Afatinib | Afatinib | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR, HER2, HER4 | Oral | Jul 14, 2026 | In Use | |
| 40051-0604-12 | 40051-0604 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 25021-0235-51 | 25021-0235 | Gemcitabine Hydrochloride | Gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 15, 2022 | In Use | |
| 00078-0698-51 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Apr 28, 2017 | In Use | |
| 51991-0991-28 | 51991-0991 | Everolimus | Everolimus | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 28, 2025 | In Use | |
| 00409-0183-25 | 00409-0183 | GEMCITABINE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 9, 2013 | In Use | |
| 16729-0130-53 | 16729-0130 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
| 68083-0343-05 | 68083-0343 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Dec 23, 2019 | In Use | |
| 70121-1218-07 | 70121-1218 | Doxorubicin | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 17, 2017 | In Use | |
| 00069-0655-30 | 00069-0655 | Talazoparib | Talzenna | 0.75 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
| 71777-0390-01 | 71777-0390 | LAROTRECTINIB | VITRAKVI | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov 26, 2018 | In Use | |
| 23155-0649-41 | 23155-0649 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct 1, 2019 | In Use | ||
| 60505-3803-07 | 60505-3803 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use | |
| 42737-0101-05 | 42737-0101 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 31, 2018 | Jan 24, 2019 | In Use |
| 00781-2691-75 | 00781-2691 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
| 00004-1101-75 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 30, 1998 | Dec 31, 2014 | No Longer Used |
| 69945-0452-01 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 00245-0822-04 | 00245-0822 | Everolimus | TORPENZ | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 21, 2025 | In Use |
Found 12611 results — Export these results
Home